Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy

Pharmacogenetics and Genomics

Volumn 21, Issue 10, 2011, Pages 624-630

  Ufer, Mike ^a   Von Stülpnagel, Celina ^b   Muhle, Hiltrud ^a   Haenisch, Sierk ^a   Remmler, Cornelia ^a   Majed, Amani ^a   Plischke, Herbert ^c   Stephani, Ulrich ^a,d   Kluger, Gerhard ^b   Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Hospital for Neuropaediatrics and Neurological Rehabilitation   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Northern German Epilepsy Center   (Germany)

Author keywords

blood brain barrier; drug transport; multi drug resistance protein 2; pharmacotherapy resistance

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN 2; OXCARBAZEPINE; PHENOBARBITAL; SULTIAME; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ALLELE; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CAUCASIAN; CHILD; DRUG RESPONSE; DRUG TRANSPORT; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

EID: 80052772274     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283498131     Document Type: Article

References (37)

1. Neville BG. Epilepsy in childhood. BMJ 1997; 315:924-930.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314-319. (Pubitemid 30075244)
3. Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001; 57:2259-2264. (Pubitemid 34016461)
4. Schmidt D, Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46:858-877. (Pubitemid 40847354)
5. Sisodiya SM, Thom M. Widespread upregulation of drug-resistance proteins in fatal human status epilepticus. Epilepsia 2003; 44:261-264. (Pubitemid 36206033)
6. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2:473-481. (Pubitemid 36876104)
7. Kasperaviciute D, Sisodiya SM. Epilepsy pharmacogenetics. Pharmacogenomics 2009; 10:817-836.
8. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009; 50:898-903.
9. Cascorbi I. ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics? Clin Pharmacol Ther 2010; 87:15-18.
10. Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS, Zulkifli SZ, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 2010; 19:339-346.
11. Nurmohamed L, Garcia-Bournissen F, Buono RJ, Shannon MW, Finkelstein Y. Predisposition to epilepsy-does the ABCB1 gene play a role? Epilepsia 2010; 51:1882-1885.
12. Mosyagin I, Runge U, Schroeder HW, Dazert E, Vogelgesang S, Siegmund W, et al. Association of ABCB1 genetic variants 3435C ≥ T and 2677G≥T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 2008; 49:1555-1561.
13. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003; 306:124-131. (Pubitemid 36734365)
14. Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007; 7:56-65. (Pubitemid 46322080)
15. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 2011; 11:25-34.
16. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicintype induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008; 18:357-365. (Pubitemid 351367529)
17. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C> T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 2009; 19:353-362.
18. Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K. ABCC2 haplotype is not associated with drug-resistant epilepsy. J Pharm Pharmacol 2008; 60:631-635. (Pubitemid 351589051)
19. Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, Lee SH, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 2010; 20:249-256.
20. Von Stulpnagel C, Plischke H, Zill P, Baumel C, Spiegel R, Gruber R, et al. Letter: lack of association between MDR1 polymorphisms and pharmacoresistance to anticonvulsive drugs in patients with childhoodonset epilepsy. Epilepsia 2009; 50:1835-1837.
21. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42:796-803. (Pubitemid 32605946)
22. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-175.
23. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169. (Pubitemid 37414228)
24. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6:591-602. (Pubitemid 41059334)
25. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007; 52:333-346. (Pubitemid 46123353)
26. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008; 55:1364-1375.
27. Siddiqui A, Kerb R,Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442-1448. (Pubitemid 36407173)
28. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 2004; 14:1333-1344. (Pubitemid 39029230)
29. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal Bianco A, Zimprich A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004; 63: 1087-1089. (Pubitemid 39287922)
30. Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/ leucovorin (FOLFIRI). Biol Pharm Bull 2008; 31:2137-2142.
31. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006; 86:1179-1236. (Pubitemid 44521651)
32. Sillanpaa M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129:617-624. (Pubitemid 43278224)
33. Gibbs JP, Adeyeye MC, Yang Z, Shen DD. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Epilepsy Res 2004; 58:53-66. (Pubitemid 38447136)
34. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007; 320:331-343. (Pubitemid 46025748)
35. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004; 129:349-360. (Pubitemid 39388854)
36. Kubota H, Ishihara H, Langmann T, Schmitz G, Stieger B,Wieser HG, et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006; 68:213-228.
37. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen HW, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51:1069-1077.